Clare, Gerry http://orcid.org/0000-0003-3029-8832
Kempen, John H. http://orcid.org/0000-0002-2967-4792
Pavésio, Carlos
Funding for this research was provided by:
Prof. Kempen received funding from Sight for Souls (Bellevue, Washington, USA) and the Massachusetts Eye and Ear Global Surgery Program
Article History
Received: 13 August 2023
Revised: 10 January 2024
Accepted: 26 January 2024
First Online: 14 February 2024
Competing interests
: John H. Kempen: Betaliq (Equity Owner); Tarsier Pharma (Equity Owner). The remaining authors declare no conflict of interest.